Nearly 44% of breast cancer patients taking CBD for aromatase inhibitor joint pain achieved a meaningful reduction in worst pain over 15 weeks.
Oncologists; breast cancer patients experiencing AIMSS; CBD researchers; cancer supportive care specialists.
43.6% of patients achieved clinically meaningful pain reduction with CBD
What the researchers found
In a phase 2 clinical trial, 17 of 39 breast cancer patients (43.6%) taking CBD (Epidiolex, titrated to 100mg twice daily) achieved at least a 2-point reduction in worst pain from aromatase inhibitor therapy. Among the 28 who completed the study, average worst pain decreased by 2.36 points over 15 weeks.
Why it matters
Aromatase inhibitor joint pain causes some breast cancer patients to stop life-saving cancer treatment. Finding a tolerable pain management option like CBD could improve both quality of life and cancer outcomes by keeping patients on their medication.
The numbers in context
39 eligible patients enrolled. 28 completed treatment. 11 discontinued (5 toxicity, 6 patient preference). 17/39 (43.6%, 95% CI 28-60%) met primary endpoint. Worst pain improved 0.13 points per week (p<0.001). Completers: average 2.36-point pain reduction (95% CI -3.22 to -1.49). CBD dose: 100mg BID.
How the study worked
Phase 2 clinical trial of 39 women with stage 0-3 hormone receptor-positive breast cancer experiencing aromatase inhibitor-associated musculoskeletal symptoms. CBD (Epidiolex) titrated to 100mg twice daily over 4 weeks, total treatment 15 weeks. Used paired t-tests and linear mixed models.
What this study cannot tell us
No placebo control group. Small sample (39 patients). Open-label design allows placebo effects. 28% dropout rate. Pharmaceutical-grade CBD (Epidiolex) may differ from commercially available products.
How to read the evidence
Small phase 2 trial without placebo control; promising but needs confirmation in larger randomized studies.
When this study was published
2025 study
The bigger picture
AIMSS affects up to half of breast cancer patients on aromatase inhibitors, and current pain management options are limited. This pilot suggests CBD warrants further study, though it helped some patients and not others.
Questions still open
- Which patients are most likely to benefit from CBD for AIMSS? Would a placebo-controlled trial confirm these results? Could different CBD dosing strategies improve tolerability and reduce dropouts?
Common questions
What is AIMSS?
What type of CBD was used?
Read the original research
Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Breast Cancer.
Cancer medicine, 14(15), e71117
Citation
Fleege, Nicole M G; Miller, Elise A; Kidwell, Kelley M; Zacharias, Zeb R; Houtman, Jon; Scheu, Kelly; Kemmer, Kathleen; Boehnke, Kevin F; Henry, N Lynn. (2025). Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Breast Cancer.. Cancer medicine, 14(15), e71117. https://doi.org/10.1002/cam4.71117
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk